Zacks Investment Research upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
Several other brokerages have also recently weighed in on CRSP. SunTrust Banks reaffirmed a buy rating and set a $65.00 price objective on shares of Crispr Therapeutics in a research note on Friday, March 9th. Piper Jaffray Companies reaffirmed an overweight rating and set a $53.70 price objective (down from $67.00) on shares of Crispr Therapeutics in a research note on Friday, March 9th. Barclays upped their price objective on shares of Crispr Therapeutics from $29.00 to $59.00 and gave the stock an overweight rating in a research note on Wednesday, March 7th. JMP Securities began coverage on shares of Crispr Therapeutics in a research note on Thursday, March 8th. They set an outperform rating and a $69.00 price objective on the stock. Finally, ValuEngine raised shares of Crispr Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 28th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $53.53.
In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $18.90, for a total transaction of $283,500.00. Following the sale, the insider now directly owns 130,204 shares of the company’s stock, valued at $2,460,855.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Woiwode sold 3,059 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.29, for a total transaction of $62,067.11. Following the sale, the director now directly owns 4,959 shares in the company, valued at $100,618.11. The disclosure for this sale can be found here. Insiders have sold 298,850 shares of company stock worth $7,545,365 over the last three months. 39.98% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC lifted its holdings in Crispr Therapeutics by 26.4% in the fourth quarter. Millennium Management LLC now owns 95,130 shares of the company’s stock valued at $2,234,000 after buying an additional 19,858 shares during the period. Paloma Partners Management Co acquired a new position in Crispr Therapeutics in the fourth quarter valued at approximately $290,000. Raymond James & Associates lifted its holdings in Crispr Therapeutics by 70.2% in the fourth quarter. Raymond James & Associates now owns 82,838 shares of the company’s stock valued at $1,945,000 after buying an additional 34,178 shares during the period. Two Sigma Investments LP acquired a new position in Crispr Therapeutics in the fourth quarter valued at approximately $1,079,000. Finally, Morgens Waterfall Vintiadis & Co. Inc. acquired a new position in Crispr Therapeutics in the fourth quarter valued at approximately $704,000. Institutional investors and hedge funds own 27.29% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades Crispr Therapeutics (CRSP) to “Hold”” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3260793/zacks-investment-research-upgrades-crispr-therapeutics-crsp-to-hold.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.